This content is machine translated Ewing's Sarcoma Management of the second most common primary malignant bone tumor Therapy of choice for Ewing’s sarcoma includes neoadjuvant chemotherapy, tumor resection, and postoperative chemotherapy with/without radiotherapy. In this context, interdisciplinary management at an appropriate center is of crucial importance.
View Post 1 min This content is machine translated Special report: maintenance therapy of relapsed ovarian cancer. Niraparib approved with individual starting doses In October 2018, the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib (Zejula®) was approved for the maintenance treatment of relapsed ovarian cancer [1]. It can be used regardless of BRCA mutation…
View Post 10 min This content is machine translated Bone Sarcomas Treatment of primary bone tumors of the pelvis Surgical resection represents the mainstay of therapy for pelvic bone sarcomas. Treatment is complex and should be individualized. By sharing data and expert knowledge, the disease can be better understood.…
View Post 9 min This content is machine translated Regional hyperthermia in oncology A practical overview Hyperthermia is a potent radio-sensitizer. The evidence base is good, especially for re-irradiation of tumor recurrences in pre-exposed areas. Thermal radiotherapy as part of primary curative therapy is currently being…
View Post 4 min This content is machine translated 28th German Skin Cancer Congress 2018, Stuttgart Update on immunotherapy of malignant melanoma Combination immunotherapy, adjuvant immune checkpoint blockade, and long-term survival after PD-1 inhibitor therapy were the topics of two satellite symposia at the German Skin Cancer Congress.
View Post 6 min This content is machine translated DGHO in Vienna Prostate and breast cancer: the future belongs to combined therapies Treatment options are often limited in both prostate and breast carcinoma. The search for new effective drugs and combination therapies is therefore the primary goal of current studies.
View Post 10 min This content is machine translated Developments in the field of acute leukemias The beginning of a new era in therapy Therapy for AML and ALL is on the move. In the future, it will be much more differentiated. Some new options have already been approved, while others are in development…
View Post 9 min This content is machine translated Known and new about stem cell transplantation Quo vadis, cell therapy? More volunteer donors and reduced-intensity conditioning now make allogeneic stem cell transplantation accessible to a larger patient population. In turn, autologous stem cell transplantation also stops autoimmune diseases via “rebooting”…
View Post 4 min This content is machine translated EHA in Stockholm CAR-T cells – New therapeutic approach for multiple myeloma There are new therapeutic approaches in multiple myeloma. For example, the efficacy and safety of CAR-T cells are being studied. In particular, they could be applicable in the refractory and…
View Post 5 min This content is machine translated Medidays Zurich Update on the workup of incidentalomas of the pituitary gland What should be considered regarding diagnosis and treatment of pituitary adenomas? To what extent is a distinction between hormone-secreting and hormone-inactive incidentalomas relevant to treatment? The endocrinology session at this…
View Post 10 min This content is machine translated Cardio-Oncology Challenges of new cancer therapies Innovative therapies have improved the prognosis of many oncological diseases. A major limitation for the individual prognosis are disease- and therapy-associated cardiovascular complications. Even rare events can have serious consequences.
